Jardiance vs Metformin: Switching Between Them Safely

Why Patients Switch Between These Two Drugs

The most common reason for switching from metformin to Jardiance is persistent gastrointestinal side effects. About 25% of metformin users report diarrhea, nausea, or abdominal cramping that does not resolve even with extended-release formulations [1]. A second driver is new evidence of cardiovascular disease or heart failure, where SGLT2 inhibitors carry stronger outcome data.

Switches in the opposite direction (Jardiance to metformin) happen less often but are not rare. Cost is the primary motivator. Generic metformin costs as little as $4 per month at many pharmacies, while brand-name Jardiance averages $570 to $620 without coverage. Genital mycotic infections, which affect roughly 6% to 8% of women and 3% to 4% of men on SGLT2 inhibitors, also prompt some patients to move back to metformin [2].

A third scenario involves adding one drug to the other rather than a full swap. The 2022 ADA Standards of Medical Care endorse combination therapy with metformin plus an SGLT2 inhibitor for patients with atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease [3]. So "switching" sometimes means "stacking."

How These Drugs Work Differently

Metformin reduces hepatic glucose output and improves peripheral insulin sensitivity without stimulating insulin secretion. It has been the default first-line agent for type 2 diabetes since the UKPDS 34 trial (N=753) demonstrated a 32% reduction in any diabetes-related endpoint and a 42% reduction in diabetes-related death compared to conventional dietary therapy [4]. That trial, published in The Lancet in 1998, remains the foundational evidence for metformin's cardiovascular benefit in overweight patients with type 2 diabetes.

Jardiance works through an entirely different pathway. It blocks the sodium-glucose cotransporter 2 in the proximal renal tubule, causing the kidneys to excrete approximately 60 to 80 grams of glucose per day into the urine. The EMPA-REG OUTCOME trial (N=7,020) showed a 38% relative risk reduction in cardiovascular death among patients with type 2 diabetes and established cardiovascular disease treated with empagliflozin versus placebo [5]. That result, published in the New England Journal of Medicine in 2015, changed practice guidelines worldwide.

Because the mechanisms do not overlap, the two drugs can be used together. They can also replace each other without pharmacokinetic conflict.

Step-by-Step: Switching from Metformin to Jardiance

A prescriber will typically stop metformin and start Jardiance 10 mg on the same day. No taper is required for metformin because it does not cause rebound hyperglycemia on discontinuation.

The standard protocol looks like this. Confirm eGFR is above 20 mL/min/1.73 m² (the FDA-approved threshold for empagliflozin initiation in type 2 diabetes). Stop metformin. Start Jardiance 10 mg once daily, taken in the morning. Recheck A1C in 8 to 12 weeks. If A1C remains above target, increase to 25 mg or add a second agent [6].

Patients should expect increased urination in the first 1 to 2 weeks. Blood pressure may drop by 3 to 5 mmHg systolic due to the osmotic diuretic effect. Advise adequate hydration, particularly in patients over age 65 or those on antihypertensives.

One clinical consideration that guidelines do not spell out clearly: if a patient was taking metformin primarily for polycystic ovary syndrome (PCOS) or prediabetes, the switch to Jardiance is off-label for those indications. Jardiance carries FDA approval only for type 2 diabetes, heart failure (HFrEF and HFpEF), and chronic kidney disease.

Step-by-Step: Switching from Jardiance to Metformin

This direction requires slightly more attention to GI tolerability. Metformin is started at 500 mg once or twice daily and titrated upward over 2 to 4 weeks to minimize diarrhea and nausea. The full therapeutic dose is typically 1,500 to 2 to 000 mg per day.

Stop Jardiance on day one of the switch. Start metformin 500 mg with the evening meal. Increase by 500 mg every 1 to 2 weeks as tolerated. Recheck A1C after 12 weeks at the target dose. If GI symptoms are problematic, switch to metformin extended-release (ER), which reduces GI side effects by roughly 50% compared to immediate-release formulations [7].

The glycosuric effect of Jardiance wears off within 24 to 48 hours of the last dose. Patients may notice a transient 15 to 30 mg/dL rise in fasting glucose during the first week, simply because the kidneys are no longer dumping glucose. This is expected. It does not indicate metformin failure.

A1C and Weight: What Changes After the Switch

Both drugs reduce A1C by a similar magnitude in head-to-head analyses, though no large randomized trial has directly compared empagliflozin monotherapy to metformin monotherapy as primary endpoints.

A network meta-analysis published in Diabetes, Obesity and Metabolism pooled data from 229 trials (N=121,914) and found that SGLT2 inhibitors as a class reduced A1C by 0.6% to 0.9% from baseline, while metformin reduced A1C by 0.8% to 1.2% [8]. Metformin has a slight edge in raw glucose lowering at higher doses, but the clinical significance of that 0.2% to 0.3% difference is debatable.

Weight is where the drugs diverge more clearly. Jardiance produces consistent weight loss of 2 to 3 kg over 24 weeks, driven by caloric loss through glycosuria (roughly 240 to 320 kcal/day). Metformin is weight-neutral to mildly weight-reducing, with most trials showing 0.5 to 1.5 kg of loss over 6 months [9]. Patients switching from Jardiance to metformin may regain 1 to 2 kg in the first 3 months. This is fluid and caloric, not a sign of treatment failure.

Kidney Function: The Deciding Factor for Many Switches

Kidney function is often the clinical variable that forces the switch. Metformin labeling requires caution below eGFR 30 mL/min/1.73 m² and is contraindicated below eGFR 20 mL/min due to lactic acidosis risk, though the absolute risk is low (estimated at 3 to 10 cases per 100,000 patient-years) [10]. In practice, most clinicians reduce metformin dose at eGFR 30 to 45 and stop it below 30.

Jardiance, by contrast, received expanded FDA labeling in 2023 for use down to eGFR 20 mL/min/1.73 m² based on the EMPA-KIDNEY trial (N=6,609), which demonstrated a 28% reduction in the composite of kidney disease progression or cardiovascular death regardless of diabetes status [11].

This means a patient whose eGFR drops from 40 to 28 mL/min over time may need to switch off metformin. Jardiance becomes the logical replacement because it still provides both glycemic benefit and renal protection at that filtration rate.

The reverse is rare but possible. A patient on Jardiance whose eGFR drops below 20 would need to discontinue it and potentially start metformin if kidney function recovers (for example, after resolution of an acute kidney injury).

Cardiovascular Considerations When Choosing

The cardiovascular profiles of these drugs differ in important ways that affect switching decisions.

Metformin's cardiovascular evidence comes primarily from UKPDS 34 [4], a trial conducted in newly diagnosed, overweight patients with type 2 diabetes. The 32% reduction in diabetes-related endpoints and 36% reduction in all-cause mortality were significant, but the trial enrolled only 753 patients in the metformin arm and used a conventional (dietary) control, not a placebo with modern standard of care.

"Metformin's cardiovascular benefit, while real, comes from a single trial with fewer than 800 patients conducted before statins and ACE inhibitors were routine," noted Dr. Silvio Inzucchi, Professor of Medicine at Yale School of Medicine, in a 2020 review in Circulation [12].

Jardiance's EMPA-REG OUTCOME [5] is a larger, more modern trial (N=7,020) with a placebo control on top of standard care that already included statins, antihypertensives, and antiplatelet agents. The 38% reduction in cardiovascular death is the headline number. The trial also showed a 35% reduction in heart failure hospitalization.

For patients with established ASCVD or heart failure, ADA and ESC guidelines now favor SGLT2 inhibitors over metformin as the preferred agent [3]. This does not mean metformin is inferior for primary prevention. It means the evidence base for Jardiance is stronger in secondary prevention.

"For patients with heart failure with reduced or preserved ejection fraction, empagliflozin has a Class I indication regardless of diabetes status. Metformin does not carry that indication," stated the 2022 AHA/ACC/HFSA heart failure guideline [13].

Side Effects Comparison: What to Expect After Switching

Side effect profiles are almost entirely non-overlapping, which makes switching straightforward from a tolerability standpoint.

Metformin's primary issues are gastrointestinal: diarrhea (up to 53% in clinical trials, though usually mild and self-limiting), nausea (25%), abdominal discomfort (12%), and metallic taste (3 to 5%). Long-term use is associated with vitamin B12 deficiency in 5% to 10% of patients, requiring periodic monitoring [14]. Lactic acidosis is exceedingly rare with normal kidney function.

Jardiance's side effects center on the genitourinary tract. Genital mycotic infections (vulvovaginal candidiasis, balanitis) occur in 6% to 8% of women and 3% to 4% of men [2]. Urinary tract infections are slightly more common than placebo. Volume depletion can cause orthostatic dizziness, particularly in elderly patients on diuretics. Euglycemic diabetic ketoacidosis (DKA) is a rare but serious risk, estimated at 0.5 to 1.0 events per 1,000 patient-years, primarily in patients with low insulin reserve or during acute illness [15].

A patient switching from metformin to Jardiance due to GI intolerance will typically find complete resolution of diarrhea within 3 to 5 days. A patient switching from Jardiance to metformin due to recurrent yeast infections can expect resolution within 1 to 2 weeks, though the GI adjustment period for metformin initiation may last 2 to 4 weeks.

Insurance, Cost, and Prior Authorization

Cost asymmetry is real. Generic metformin (immediate-release and extended-release) is on virtually every insurance formulary at Tier 1 pricing, typically $4 to $20 per month. Jardiance, still under patent, lists at approximately $570 to $620 per month. Most commercial plans cover it at Tier 3 with a copay of $35 to $75, but patients on high-deductible health plans or Medicare Part D may face significantly higher out-of-pocket costs [16].

Some insurers require step therapy or prior authorization for Jardiance, mandating a trial of metformin first. If metformin was discontinued for documented GI intolerance or declining renal function, this documentation expedites the prior authorization. Keep records of the specific side effects and lab values.

Empagliflozin-metformin combination tablets (Synjardy, Synjardy XR) exist for patients who need both drugs, potentially simplifying copays into a single prescription. Generic versions are not yet available as of mid-2026.

When to Use Both Instead of Switching

The binary "one or the other" framing misses an important clinical option. The ADA Standards of Care explicitly support dual therapy with metformin plus an SGLT2 inhibitor when a single agent does not achieve the A1C target or when the patient has compelling cardiovascular or renal indications [3].

Starting both drugs simultaneously is also acceptable, particularly for patients with A1C above 8.5% at diagnosis. A 2020 trial published in The Lancet Diabetes & Endocrinology demonstrated that early combination therapy reduced A1C more effectively than sequential addition, with a 0.5% greater reduction at 24 weeks [17].

The practical threshold: if A1C is 7.5% or higher on monotherapy and the patient tolerates both drugs, combination is usually preferred over a swap.

Monitoring Schedule After the Switch

Regardless of direction, the post-switch monitoring checklist is similar. Check fasting glucose 1 to 2 weeks after the switch to catch any significant glycemic excursion. Obtain A1C at 10 to 12 weeks post-switch. Measure a basic metabolic panel (BMP) at 4 weeks if switching to Jardiance, to assess creatinine and potassium. Check vitamin B12 annually if continuing or starting metformin. Monitor for genital infections at each follow-up visit if switching to Jardiance. Repeat eGFR every 3 to 6 months for patients on either drug with baseline CKD stage 3 or higher.

Patients on insulin or sulfonylureas alongside either drug should have hypoglycemia risk reassessed at the time of the switch, as the glycemic contribution of the discontinued agent may unmask or reduce hypo risk from the remaining regimen.